{
    "clinical_study": {
        "@rank": "33538", 
        "arm_group": [
            {
                "arm_group_label": "methylprednisolone", 
                "arm_group_type": "Active Comparator", 
                "description": "intravenous MP: 0.5g weekly for six weeks followed by 0.25g weekly for six weeks"
            }, 
            {
                "arm_group_label": "methylprednisolone plus prednisone", 
                "arm_group_type": "Active Comparator", 
                "description": "intravenous MP 0.5g daily for three days per week, twice, followed by 0.25g daily for three days per week, twice, and followed by tapering oral prednisone (starting with 60mg/d, then10 mg less/week than each previous week for the next 3 weeks, then20mg/week at the 5th week followed with 5mg less/week than each previous week for the next 3 weeks)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study was designed to compare the efficacy and safety of 4.5g iv MP administered in 12\n      weeks and 4 weeks."
        }, 
        "brief_title": "A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Graves' Ophthalmopathy", 
        "condition_browse": {
            "mesh_term": [
                "Eye Diseases", 
                "Graves Ophthalmopathy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients should meet the criteria of either a or b and together with c, d and e to\n             include into the study.\n\n             a. Lid retraction with any one of the following: i) Thyroid dysfunction ii) Proptosis\n             iii) Optic nerve involvement iv) Extraocular muscle involvement b. Thyroid\n             dysfunction with any one of the following: i) Proptosis ii) Optic nerve involvement\n             iii) Extraocular muscle involvement c. Exclude cases with such ophthalmological signs\n             caused by other diseases. d. Moderate to severe patients defined by EUGOGO. e.\n             Clinical activity score (CAS)\u22653/7 f. Normal function of heart, liver and kidney.\n\n        Exclusion Criteria:\n\n          -  Orbital decompression surgery needed immediately\n\n          -  History of chronic recurrent or active infection\n\n          -  History of peptic ulcer\n\n          -  Patients with a history of chronic liver disease or liver disorders\uff1b ALT or AST above\n             2.5 times upper limit of normal\n\n          -  History of HIV, hepatitis C or hepatitis B Positive\n\n          -  Cardiovascular or cerebrovascular disease clinically significant\n\n          -  Uncontrolled diabetes mellitus\n\n          -  Use of corticosteroids during 12 weeks before to inclusion period\n\n          -  Pregnant patient or patient who is planning to become pregnant during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969019", 
            "org_study_id": "CCEMD015"
        }, 
        "intervention": {
            "arm_group_label": [
                "methylprednisolone", 
                "methylprednisolone plus prednisone"
            ], 
            "intervention_name": "methylprednisolone, prednisone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Prednisone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 21, 2013", 
        "location": {
            "contact": {
                "email": "juvey1515@gmail.com", 
                "last_name": "Wei Zhu, Attending", 
                "phone": "(8621)64370045", 
                "phone_ext": "602105"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200025"
                }, 
                "name": "Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy", 
        "overall_contact": {
            "email": "guangning@medmail.com.cn", 
            "last_name": "Ning Guang, Professor", 
            "phone": "(8621)64370045", 
            "phone_ext": "665344"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "response rate", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969019"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ruijin Hospital", 
            "investigator_full_name": "Wei Zhu", 
            "investigator_title": "Attending", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "change of CAS, adverse effects and retreat", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "source": "Ruijin Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ruijin Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}